Medxy AI – Page 51

Early Intervention in Pulmonary Arterial Hypertension: The Promise of Sotatercept in the First Year Post-Diagnosis

By MedXY 10/25/2025

This article reviews a phase 3 trial analyzing sotatercept's efficacy and safety in newly diagnosed pulmonary arterial hypertension patients, highlighting its potential to reduce clinical worsening early in the disease course.

news Oncology

Revolutionizing Early-Stage Cervical Cancer Management: Insights from the SENTIX Sentinel Lymph Node Trial

By MedXY 10/25/2025

The SENTIX trial shows that sentinel lymph node biopsy without full pelvic lymphadenectomy is safe in early-stage cervical cancer, potentially reducing surgical morbidity without compromising oncologic outcomes.

news Oncology

Reevaluating Lymph Node Management in Early-Stage Cervical Cancer: Sentinel Biopsy Alone Shows Promise

By MedXY 10/25/2025

A large randomized trial finds sentinel lymph-node biopsy alone is noninferior to lymphadenectomy in early cervical cancer, with fewer complications and comparable survival outcomes.

Internal Medicine news Rheumatology

Emerging Promise of Telitacicept in Treating Systemic Lupus Erythematosus: Insights from a Phase 3 Trial

By MedXY 10/25/2025

This article reviews a pivotal phase 3 trial demonstrating telitacicept's efficacy and safety in active SLE, highlighting its potential as a novel targeted therapy.

Allergy & Immunology Hematology-Oncology news

Long-Term Safety and Efficacy of Gene Therapy for Adenosine Deaminase Deficiency

By MedXY 10/25/2025

This study demonstrates the long-term effectiveness and safety of autologous gene therapy for treating ADA deficiency, showing sustained immune function and minimal adverse effects over a median follow-up of 7.5 years.

Infectious Diseases news Pediatrics

Mass Azithromycin Administration in Malian Infants Shows No Mortality Benefit: A Large-Scale Randomized Trial

By MedXY 10/25/2025

A large randomized trial in Mali demonstrated that mass azithromycin administration to infants aged 1–11 months did not reduce mortality compared to placebo, challenging previous findings in sub-Saharan Africa.

news Oncology Respiratory

Emerging Promise of Sevabertinib for HER2-Mutant Non-Small-Cell Lung Cancer: A New Hope

By MedXY 10/25/2025

This article reviews recent clinical trial data showing sevabertinib's efficacy and safety in treating HER2-mutant NSCLC, highlighting its potential to fill an unmet therapeutic gap.

news Oncology Respiratory

Efficacy of Afatinib Combined with Chemotherapy in Post-Osimertinib EGFR-Mutated NSCLC: Insights from the NEJ025B Study

By MedXY 10/25/2025

This phase II study evaluates the effectiveness and safety of afatinib with platinum-based chemotherapy in NSCLC patients resistant to first-line osimertinib, highlighting promising outcomes and manageable toxicity.

news Oncology Respiratory

Advancing Treatment in EGFR-Mutant NSCLC: Efficacy of Amivantamab Plus Lazertinib Post-Resistances

By MedXY 10/25/2025

This article reviews the CHRYSALIS-2 cohort A study demonstrating the potential of combined amivantamab and lazertinib therapy in heavily pretreated EGFR-mutant NSCLC patients.

Oncology Respiratory

Enhanced Survival in EGFR-Mutated NSCLC: Impact of Amivantamab-Lazertinib vs. Osimertinib

By MedXY 10/25/2025

This article reviews a phase 3 trial comparing overall survival of amivantamab-lazertinib versus osimertinib in untreated EGFR-mutated advanced NSCLC, highlighting efficacy, safety, and clinical implications.

news Oncology Respiratory

Enhanced Survival in EGFR-Mutated NSCLC: The Impact of Combining Osimertinib with Chemotherapy

By MedXY 10/25/2025

This article reviews the latest evidence demonstrating improved overall survival with osimertinib combined with chemotherapy in first-line treatment of EGFR-mutated advanced non-small-cell lung cancer.

Dermatology Oncology

Nine-Year Outcomes of Nivolumab vs Ipilimumab in Resected Stage III/IV Melanoma: Sustained Survival Benefit and Safety

By MedXY 10/25/2025

The 9-year follow-up of the CheckMate 238 trial confirms that nivolumab offers longer recurrence-free survival than ipilimumab in resected stage III/IV melanoma, with durable safety and favorable distant metastasis-free survival.

news Oncology Urology

Enhancing Survival in Biochemically Recurrent Prostate Cancer: The Promising Role of Enzalutamide

By MedXY 10/25/2025

This review highlights the recent findings from the EMBARK trial demonstrating improved overall survival with enzalutamide combined with leuprolide in high-risk recurrent prostate cancer.

Oncology Otorhinolaryngology

Evaluating Atezolizumab Maintenance Therapy in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Insights from the IMvoke010 Trial

By MedXY 10/25/2025

Atezolizumab maintenance therapy after multimodal definitive treatment failed to improve event-free or overall survival in high-risk LA SCCHN patients in the phase 3 IMvoke010 trial, highlighting challenges in immunotherapy for this setting.

Oncology Pathology & Lab Medicine Urology

ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer: Translating Precision Oncology into Improved Outcomes

By MedXY 10/25/2025

This review synthesizes pivotal evidence from the IMvigor011 trial demonstrating that ctDNA-guided adjuvant atezolizumab significantly improves disease-free and overall survival in muscle-invasive bladder cancer, enabling risk-adapted immunotherapy after cystectomy.

news Oncology Urology

Long-Term Efficacy and Safety of Belzutifan in von Hippel-Lindau Disease-Associated Renal Cell Carcinoma: Insights from the 50-Month LITESPARK-004 Phase 2 Study

By MedXY 10/25/2025

Belzutifan demonstrates sustained tumor response and manageable safety over 50 months in patients with von Hippel-Lindau disease-associated renal cell carcinoma, supporting its role as a systemic therapy.

Oncology Urology

Innovative Immunotherapy Combines to Transform Treatment of HER2-Expressing Advanced Urothelial Cancer

By MedXY 10/25/2025

This study demonstrates that disitamab vedotin plus toripalimab significantly improves survival outcomes over chemotherapy in untreated HER2-positive advanced urothelial cancer.

Diabetes & Endocrinology Oncology

Targeting Tumor Hypoxia Pathways: Belzutifan’s Promise in Advanced Paraganglioma and Pheochromocytoma Treatment

By MedXY 10/25/2025

This article reviews a phase 2 trial of belzutifan, a HIF-2α inhibitor, demonstrating durable antitumor activity and manageable safety in advanced pheochromocytoma and paraganglioma, highlighting its potential as a targeted therapy.

Oncology

Cutting-Edge Treatment for EGFR-Mutated NSCLC: Sacituzumab Tirumotecan Shows Promising Survival Benefits

By MedXY 10/25/2025

A phase 3 trial demonstrates that sacituzumab tirumotecan significantly improves progression-free and overall survival in EGFR-mutated advanced NSCLC resistant to TKI therapy.

Early Intervention in Pulmonary Arterial Hypertension: The Promise of Sotatercept in the First Year Post-Diagnosis

Revolutionizing Early-Stage Cervical Cancer Management: Insights from the SENTIX Sentinel Lymph Node Trial

Reevaluating Lymph Node Management in Early-Stage Cervical Cancer: Sentinel Biopsy Alone Shows Promise

Emerging Promise of Telitacicept in Treating Systemic Lupus Erythematosus: Insights from a Phase 3 Trial

Long-Term Safety and Efficacy of Gene Therapy for Adenosine Deaminase Deficiency

Mass Azithromycin Administration in Malian Infants Shows No Mortality Benefit: A Large-Scale Randomized Trial

Emerging Promise of Sevabertinib for HER2-Mutant Non-Small-Cell Lung Cancer: A New Hope

Efficacy of Afatinib Combined with Chemotherapy in Post-Osimertinib EGFR-Mutated NSCLC: Insights from the NEJ025B Study

Advancing Treatment in EGFR-Mutant NSCLC: Efficacy of Amivantamab Plus Lazertinib Post-Resistances

Enhanced Survival in EGFR-Mutated NSCLC: Impact of Amivantamab-Lazertinib vs. Osimertinib

Enhanced Survival in EGFR-Mutated NSCLC: The Impact of Combining Osimertinib with Chemotherapy

Nine-Year Outcomes of Nivolumab vs Ipilimumab in Resected Stage III/IV Melanoma: Sustained Survival Benefit and Safety

Enhancing Survival in Biochemically Recurrent Prostate Cancer: The Promising Role of Enzalutamide

Evaluating Atezolizumab Maintenance Therapy in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Insights from the IMvoke010 Trial

ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer: Translating Precision Oncology into Improved Outcomes

Long-Term Efficacy and Safety of Belzutifan in von Hippel-Lindau Disease-Associated Renal Cell Carcinoma: Insights from the 50-Month LITESPARK-004 Phase 2 Study

Innovative Immunotherapy Combines to Transform Treatment of HER2-Expressing Advanced Urothelial Cancer

Targeting Tumor Hypoxia Pathways: Belzutifan’s Promise in Advanced Paraganglioma and Pheochromocytoma Treatment

Cutting-Edge Treatment for EGFR-Mutated NSCLC: Sacituzumab Tirumotecan Shows Promising Survival Benefits

Academic vs. Industry: Why Non-Industry Trials Are Failing to Reach the Finish Line

Real-World Implementation of RTS,S/AS01E Malaria Vaccine Reduces Severe Malaria by 58%: Evidence from the EPI-MAL-003 Phase 4 Study

Why Our Strength and Fitness Peak in Our 20s–30s — and How Exercise Can Push Back the Clock

Heart Failure Mortality: The Resilient Challenge in an Era of Declining Cardiovascular Deaths